Christine A. Penfold

1.1k total citations
16 papers, 697 citations indexed

About

Christine A. Penfold is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Oncology. According to data from OpenAlex, Christine A. Penfold has authored 16 papers receiving a total of 697 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Radiology, Nuclear Medicine and Imaging, 14 papers in Immunology and 8 papers in Oncology. Recurrent topics in Christine A. Penfold's work include Monoclonal and Polyclonal Antibodies Research (14 papers), T-cell and B-cell Immunology (8 papers) and Immune Cell Function and Interaction (6 papers). Christine A. Penfold is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (14 papers), T-cell and B-cell Immunology (8 papers) and Immune Cell Function and Interaction (6 papers). Christine A. Penfold collaborates with scholars based in United Kingdom, United States and Netherlands. Christine A. Penfold's co-authors include Martin J. Glennie, Mark S. Cragg, H.T. Claude Chan, Ruth R. French, C. Ian Mockridge, Xiaojie Yu, Tatyana Inzhelevskaya, Alison L. Tutt, Ann L. White and Steven G. Booth and has published in prestigious journals such as Nature, Nature Communications and Blood.

In The Last Decade

Christine A. Penfold

15 papers receiving 676 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Christine A. Penfold United Kingdom 13 495 388 306 210 41 16 697
Thies Rösner Germany 16 463 0.9× 309 0.8× 202 0.7× 207 1.0× 47 1.1× 30 666
Heidi H. van Ojik Netherlands 9 322 0.7× 325 0.8× 263 0.9× 245 1.2× 40 1.0× 11 620
Homer Adams United States 10 237 0.5× 195 0.5× 401 1.3× 249 1.2× 81 2.0× 25 713
Kimberly H. Harrington United States 11 206 0.4× 254 0.7× 492 1.6× 343 1.6× 48 1.2× 17 807
Louise W. Treffers Netherlands 9 449 0.9× 317 0.8× 198 0.6× 423 2.0× 19 0.5× 9 809
Jane E. Willoughby United Kingdom 11 412 0.8× 122 0.3× 233 0.8× 146 0.7× 18 0.4× 12 581
Chelsea J. Gudgeon United States 11 177 0.4× 129 0.3× 308 1.0× 220 1.0× 32 0.8× 16 532
Olga Radkevich-Brown United States 7 330 0.7× 219 0.6× 464 1.5× 127 0.6× 26 0.6× 8 636
Dmitry Pankov United States 11 344 0.7× 194 0.5× 464 1.5× 183 0.9× 28 0.7× 17 620
Johan Sein Netherlands 11 316 0.6× 147 0.4× 278 0.9× 150 0.7× 30 0.7× 17 490

Countries citing papers authored by Christine A. Penfold

Since Specialization
Citations

This map shows the geographic impact of Christine A. Penfold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christine A. Penfold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christine A. Penfold more than expected).

Fields of papers citing papers by Christine A. Penfold

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christine A. Penfold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christine A. Penfold. The network helps show where Christine A. Penfold may publish in the future.

Co-authorship network of co-authors of Christine A. Penfold

This figure shows the co-authorship network connecting the top 25 collaborators of Christine A. Penfold. A scholar is included among the top collaborators of Christine A. Penfold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christine A. Penfold. Christine A. Penfold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Chan, H.T. Claude, Tatyana Inzhelevskaya, C. Ian Mockridge, et al.. (2025). Structure-guided disulfide engineering restricts antibody conformation to elicit TNFR agonism. Nature Communications. 16(1). 3495–3495. 1 indexed citations
2.
Yu, Xiaojie, Christian M. Orr, H.T. Claude Chan, et al.. (2023). Reducing affinity as a strategy to boost immunomodulatory antibody agonism. Nature. 614(7948). 539–547. 71 indexed citations
3.
Willoughby, Jane E., Martin C. Taylor, Steven G. Booth, et al.. (2022). Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments. Journal for ImmunoTherapy of Cancer. 10(1). e003735–e003735. 28 indexed citations
4.
Roghanian, Ali, Robert Oldham, H.T. Claude Chan, et al.. (2022). FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms. Cell Reports. 40(3). 111099–111099. 16 indexed citations
5.
Orr, Christian M., Xiaojie Yu, H.T. Claude Chan, et al.. (2022). Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility. Science Immunology. 7(73). eabm3723–eabm3723. 30 indexed citations
6.
Chan, H.T. Claude, Michael J. Marshall, Christine A. Penfold, et al.. (2022). Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. Communications Biology. 5(1). 229–229. 12 indexed citations
7.
Yu, Xiaojie, Sonya James, James H. Felce, et al.. (2021). TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity. Communications Biology. 4(1). 772–772. 35 indexed citations
8.
Yu, Xiaojie, H.T. Claude Chan, Christine A. Penfold, et al.. (2020). Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity. Cancer Cell. 37(6). 850–866.e7. 48 indexed citations
9.
Buchan, Sarah L., Stephen M. Thirdborough, Vadim Y. Taraban, et al.. (2018). PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell–Driven Antitumor Immunity. Clinical Cancer Research. 24(10). 2383–2394. 82 indexed citations
10.
Cox, Kerry L., Christine A. Penfold, Ruth R. French, et al.. (2018). Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking. Scientific Reports. 8(1). 2278–2278. 30 indexed citations
11.
Yu, Xiaojie, H.T. Claude Chan, Christian M. Orr, et al.. (2018). Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies. Cancer Cell. 33(4). 664–675.e4. 75 indexed citations
12.
Chan, H.T. Claude, Christine A. Penfold, Sonya James, et al.. (2016). Anti-CD27 Enhances Lymphoma Immunotherapy through Profound Myeloid Cell Recruitment. Blood. 128(22). 3024–3024. 1 indexed citations
13.
White, Ann L., H.T. Claude Chan, Ruth R. French, et al.. (2014). Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies. Cancer Cell. 27(1). 138–148. 125 indexed citations
14.
Williams, Emily L., Alison L. Tutt, Stephen A. Beers, et al.. (2013). Immunotherapy Targeting Inhibitory Fcγ Receptor IIB (CD32b) in the Mouse Is Limited by Monoclonal Antibody Consumption and Receptor Internalization. The Journal of Immunology. 191(8). 4130–4140. 23 indexed citations
15.
Williams, Emily L., Alison L. Tutt, Ruth R. French, et al.. (2012). Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B). European Journal of Immunology. 42(8). 2109–2120. 31 indexed citations
16.
Tutt, Alison L., Ruth R. French, Tim Illidge, et al.. (1998). Monoclonal Antibody Therapy of B Cell Lymphoma: Signaling Activity on Tumor Cells Appears More Important Than Recruitment of Effectors. The Journal of Immunology. 161(6). 3176–3185. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thies Rösner Breakdown of academic impact, for papers by Heidi H. van Ojik Breakdown of academic impact, for papers by Homer Adams Breakdown of academic impact, for papers by Kimberly H. Harrington Breakdown of academic impact, for papers by Louise W. Treffers Breakdown of academic impact, for papers by Jane E. Willoughby Breakdown of academic impact, for papers by Chelsea J. Gudgeon Breakdown of academic impact, for papers by Olga Radkevich-Brown Breakdown of academic impact, for papers by Dmitry Pankov Breakdown of academic impact, for papers by Johan Sein
Rankless by CCL
2026